ALSFRS-R

Published research on ALSFRS-R.

DrugsJun 5, 2026

Masitinib for ALS: AB10015 Reports 42.3% 5-Year Survival

A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. …

Read article →

Neurodegenerative DiseasesMay 30, 2026

ALS CSF Proteomics Found 399 Candidate Proteins and a 5-Protein Panel

A 2026 cerebrospinal-fluid proteomics preprint involving 87 amyotrophic lateral sclerosis (ALS) patients, 89 healthy controls, and 61 neurological controls reported 399 ALS candidate protein…

Read article →

PsychologyMay 28, 2026

ALS Entropy Analysis Finds 5-Month Signal Hidden by ALSFRS Scores

A 2026 PRO-ACT analysis of amyotrophic lateral sclerosis (ALS) trial data found a signal that ordinary ALSFRS total-score slopes cannot even express: Shannon entropy trajectories diverged be…

Read article →